Investigational drug · Phase 3
MCV4
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Meningococcal Meningitis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
18
Any phase or sponsor naming "MCV4"
First trial start
2024
Mar 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MCV4", any sponsor or status.
Conditions studied
As listed on its trial records.
- Meningococcal Meningitis
Largest trials
Live from ClinicalTrials.gov: studies naming "MCV4" as an intervention, largest first.
Neuroganics LLCIndustry
NCT05095844 · 100,000 participants (planned) · Start Mar 15, 2022 · Primary completion Apr 1, 2024
Drug: vaccinated · For: COVID-19; Vaccine Adverse Reaction; Vaccine Reaction and 10 more
Sites: Northglenn, Colorado
JhpiegoAcademic, hospital or other
NCT01096134 · 8,000 participants · Start Jan 2011 · Primary completion Nov 2012
Drug: HPV Vaccine (Gardasil) · For: Cervical Cancer
Sites: Cebu, Philippines; Quezon, Philippines; Nakhon Si Thammarat, Thailand · 10 sites in all
- Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccinePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT02842853 · 3,344 participants · Start Jul 15, 2016 · Primary completion Feb 28, 2017
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine · For: Meningitis; Meningococcal Meningitis; Meningococcal Infections
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 89 sites in all
CanSino Biologics Inc.Industry
NCT06389513 · 3,011 participants · Start Jun 12, 2024 · Primary completion Apr 10, 2026
Drug: MCV4 · For: Epidemic Meningitis
Sites: Nanjing, China
- A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of AgePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01461980 · 2,648 participants · Start Sep 28, 2011 · Primary completion May 8, 2014
Drug: rLP2086 + MCV4 + Tdap; MCV4 + Tdap + saline and 1 more · For: Vaccines; Meningococcal Vaccines
Sites: Birmingham, Alabama; Daphne, Alabama; Chandler, Arizona · 117 sites in all
- Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 YearsPivotal-lookingStatus unknown
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdIndustry
NCT06314685 · 2,450 participants · Start Dec 10, 2021 · Primary completion Aug 30, 2024
Drug: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine; Group A and C Meningococcal Polysaccharide Vaccine and 1 more · For: Healthy Population
Sites: Changsha, China
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 YearsPivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT06131554 · 1,480 participants · Start Mar 20, 2024 · Primary completion Jul 12, 2024
Drug: batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4); batch 2 of MCV4 and 2 more · For: Meningococcal Meningitis
Sites: Surabaya, Indonesia
- Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years OldPivotal-lookingRecruiting
EyeGene Inc.Academic, hospital or other
NCT07204457 · 1,123 participants (planned) · Start Oct 15, 2025 · Primary completion Sep 2026
Drug: EG-MCV4; Menveo · For: Meningococcal Infections
Sites: Seoul, South Korea
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old PopulationPivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT06011200 · 1,000 participants · Start Sep 16, 2023 · Primary completion Dec 11, 2023
Drug: MCV4; MSPV4 · For: Epidemic Meningitis
Sites: Shanyang, China
- A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year OldsPivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT06700148 · 840 participants · Start Dec 14, 2024 · Primary completion Feb 19, 2025
Drug: MCV4; MPSV4 · For: Meningococcal Meningitis
Sites: Dengfeng, China; Kaifeng, China
Newest research
PubMed records naming it or its code names, newest first.
- "Why should I pay for this vaccine?" - Norwegian adolescents views on meningococcal vaccination.
Gleditsch RN, Watle SV, Hansen BT, et al. · BMC Public Health 2026
- Online Decision Support for Implementing Evidence-Based HPV Vaccination Strategies in Texas Safety-Net Pediatric Clinics: Impact on HPV, MCV, and Tdap Initiation.
Shegog R, Sun H, Frost EL, et al. · Healthcare (Basel) 2026
- Characterization and vaccine-induced immunogenicity of a re-emerging Neisseria meningitidis serogroup Y in Tianjin, China.
Zhang G, Li W, Sui X, et al. · Vaccine 2026
- Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.
Villagomez-Martinez S, Kharit S, Galustyan A, et al. · Hum Vaccin Immunother 2025
- COVID-19 Impact on Adolescent Vaccination Administration Rates in the U.S. Military Health System.
Wilder J, Ha S, Ji YS, et al. · J Adolesc Health 2025
Also in development for Meningococcal Meningitis
- MPSV4Phase 32 trials
CanSino Biologics Inc. · Meningococcal Meningitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.